申请人:Zeneca Limited
公开号:US05955464A1
公开(公告)日:1999-09-21
The invention concerns 4-anilinoquinazoline derivatives of the formula I ##STR1## wherein m is 1 or 2; each R.sup.1 includes hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy; n is 1, 2 or 3; each R.sup.2 includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; and Ar is a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to four nitrogen heteroatoms, or Ar is a 5-, 6-, 9- or 10-membered nitrogen-linked unsaturated heterocyclic moiety containing up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo such as 2-oxo-4-imidazolin-1-yl; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.
这项发明涉及式I的4-苯胺基喹唑啉衍生物
其中m为1或2;每个R.sup.1包括氢、卤代、(1-4C)烷基和(1-4C)烷氧基;n为1、2或3;每个R.sup.2包括氢、羟基、卤代和(1-4C)烷基;Ar为含有最多四个氮杂原子的5-或9-成员氮链杂芳基团,或Ar为含有最多三个氮杂原子的5-、6-、9-或10-成员氮链不饱和杂环基团,其带有一个或两个从氧代和硫代氧代中选择的取代基,如2-氧代-4-咪唑啉-1-基;或其药学上可接受的盐;它们的制备方法,含有它们的药物组合物,以及在治疗增生性疾病如癌症中利用这些化合物的受体酪氨酸激酶抑制性能。